Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418068 | 0.86 | CYP1A2 (0.55) | CPA3CYP2C19FOLH1CYP1A2CPA1 | |
| SCHEMBL7076099 | 0.84 | GRIK1 (0.59) | CYP2C19FOLH1CYP1A2CPB2 | |
| SCHEMBL27682962 | 0.81 | CYP1A2 (0.50) | CPA3CYP2C19FOLH1CYP1A2CPA1 | |
| SCHEMBL7434987 | 0.81 | CYP1A2 (0.66) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL9224446 | 0.81 | CYP2C19 (0.46) | CYP2C19FOLH1CYP1A2 | |
| SCHEMBL7608459 | 0.81 | CPA3 (0.63) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL9107156 | 0.80 | CNR2 (0.47) | FOLH1 | |
| SCHEMBL8500821 | 0.80 | CYP1A2 (0.53) | CPA3CYP2C19CYP1A2CPA1 | |
| SCHEMBL8500824 | 0.80 | CYP1A2 (0.53) | CPA3CYP2C19CYP1A2CPA1 | |
| SCHEMBL22647059 | 0.78 | FOLH1 (0.79) | FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1019369-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5902817-A | 2-SULFINYL OR SULFONYLPENTANDIOIC ACIDS; INHIBITORS OF N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE; GLUTAMATE ABNORMALITIES; PROSTATES; ANTIEPILEPTIC AND -ISCHEMIC AGENTS; STROKES; ANALGESICS; NERVOUS SYTEM INJURIES; | GUILFORD PHARMACEUTICALS INC. (US) | 1999-05-11 | — | — | US | disclosed |
| WO-1998045257-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | CPA3 193/4885CYP2C19 3044/4885FOLH1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.